<DOC>
	<DOC>NCT01155661</DOC>
	<brief_summary>The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in patients with major depressive disorder (MDD) who are partial responders to their SSRI treatment.</brief_summary>
	<brief_title>A Safety Study in Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Adults competent and able to give informed consent Women of childbearing potential may participate but must test negative for pregnancy at the time of study entry; both women/men agree to use a reliable method of birth control Patients who are being treated with one of the following SSRIs: escitalopram, citalopram, sertraline, fluoxetine, paroxetine, and fluvoxamine; for at least 6 weeks prior to investigational product dispensing with at least the last 4 weeks at a stable, optimized dose Drug and dosage should be within the labeling guidelines for the specific country Meet criteria for MDD (Major Depressive Disorder), as defined by the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSMIVTR) criteria Meet criteria for partial response, as defined by investigator's opinion that patient has experienced a minimal clinically meaningful improvement with SSRI Have a Grid Hamilton Rating Scale for Depression (GRIDHAMD17) total score greater than or equal to 16 at screening Have less than or equal to 75 percent improvement on the current SSRI at screening determined by the Massachusetts General Hospital Antidepressant Response Questionnaire (MGHATRQ) Meet all other inclusion criteria per protocol Presence of another primary psychiatric illnesses: Have had or currently have any additional ongoing DSMIVTR Axis 1 condition other than major depression within 1 year of screening Have had any anxiety disorder that was considered a primary diagnosis within the past year (including panic disorder, obsessivecompulsive disorder, posttraumatic stress disorder, generalized anxiety disorder, and social phobia, but excluding specific phobias) Have a current or previous diagnosis of a bipolar disorder, schizophrenia, or other psychotic disorder Have a history of substance abuse and/or dependence within the past 1 year (drug categories defined by DSMIVTR), not including caffeine and nicotine Have an Axis II disorder that, in the judgment of the investigator, would interfere with compliance with protocol Unstable medical conditions that contraindicate the use of LY2216684 Have any diagnosed medical condition which could be exacerbated by noradrenergic agents including unstable hypertension, unstable heart disease, tachycardia, tachyarrhythmia, narrowangled glaucoma, urinary hesitation or retention Use of excluded concomitant or psychotropic medication other than SSRI Have initiated or discontinued hormone therapy within the previous 3 months of prior to enrollment History of treatment resistant depression as shown by: Have had lack of response of the current depressive episode to 2 or more adequate courses of antidepressant therapy at a clinically appropriate dose for at least 4 weeks, or in the judgment of the investigator, the patient has treatmentresistant depression Have a history of electroconvulsive therapy, transcranial magnetic stimulation, or psychosurgery within the last year Meet any other exclusion criteria per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>